The quest for the grail: Multidimensional efforts for understanding and targeting severe asthma

European Respiratory Journal

Volumn 46, Issue 5, 2015, Pages 1227-1231

  Gaga, Mina ^a   Brand, Paul L P ^b,c   Thomson, Neil C ^d  

^a Athens Chest Hospital   (Greece)

^b ISALA HOSPITAL   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; MONOCLONAL ANTIBODY;

ADVERSE DRUG REACTION; AIRWAY OBSTRUCTION; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ALLERGY; ASTHMA; CHRONIC DISEASE; COHORT ANALYSIS; COMORBIDITY; CROSS-SECTIONAL STUDY; CYSTIC FIBROSIS; DIAGNOSTIC TEST; DISEASE CONTROL; DISEASE COURSE; DISEASE EXACERBATION; DISEASE MARKER; DISEASE SEVERITY; DRUG TREATMENT FAILURE; EOSINOPHILIA; GENETIC SCREENING; HUMAN; MEDICAL TECHNOLOGY; MOLECULAR BIOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; REVIEW; RISK FACTOR; SYMPTOM; TREATMENT RESPONSE; WHEEZING;

ASTHMA; HUMANS;

EID: 84946576804     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01414-2015     Document Type: Review

References (38)

1. Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010; 363: 1991-2003.
2. Rosell R, Karachaliou N. Lung cancer in 2014: optimizing lung cancer treatment approaches. Nat Rev Clin Oncol 2015; 12: 75-76.
3. López-González R, León L, Loza E, et al. Adherence to biologic therapies and associated factors in rheumatoid arthritis, spondyloarthritis and psoriatic arthritis: a systematic literature review. Clin Exp Rheumatol 2015; 33: 559-569.
4. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343-373.
5. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2015. Available from www.ginasthma.org
6. Hekking PP, Wener RR, Amelink M, et al. The prevalence of severe refractory asthma. J Allergy Clin Immunol 2015; 135: 896-902.
7. Jarjour NN, Erzurum SC, Bleecker ER, et al. Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. Am J Respir Crit Care Med 2012; 185: 356-362.
8. Lenney W, McKay AJ, Tudur Smith C, et al. Management of Asthma in School age Children On Therapy (MASCOT): a randomised, double-blind, placebo-controlled, parallel study of efficacy and safety. Health Technol Assess 2013; 17: 1-218.
9. de Groot EP, Kreggemeijer WJ, Brand PL. Getting the basics right resolves most cases of uncontrolled and problematic asthma. Acta Paediatr 2015; 104: 916-921.
10. Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011; 154: 573-582.
11. Deschildre A, Marguet C, Salleron J, et al. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur Respir J 2013; 42: 1224-1233.
12. Castro M, Rubin AS, Laviolette M, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med 2010; 181: 116-124.
13. Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. J Allergy Clin Immunol 2015; 135: 299-310.
14. Barnes PJ, Bonini S, Seeger W, et al. Barriers to new drug development in respiratory disease. Eur Respir J 2015; 45: 1197-1207.
15. Lötvall J, Akdis CA, Bacharier LB, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011; 127: 355-360.
16. Fahy JV. Type 2 inflammation in asthma-present in most, absent in many. Nat Rev Immunol 2015; 15: 57-65.
17. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371: 1198-1207.
18. Ortega H, Chupp G, Bardin P, et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. Eur Respir J 2014; 44: 239-241.
19. Arron JR, Choy DF, Scheerens H, et al. Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma. Ann Am Thorac Soc 2013; 10: Suppl., S206-S213.
20. Bracken M, Fleming L, Hall P, et al. The importance of nurse-led home visits in the assessment of children with problematic asthma. Arch Dis Child 2009; 94: 780-784.
21. The ENFUMOSA Study Group. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 2003; 22: 470-477.
22. Fitzpatrick AM, Teague WG, Meyers DA, et al. Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. J Allergy Clin Immunol 2011; 127: 382-389.
23. Kupczyk M, Dahlén B, Sterk PJ, et al. Stability of phenotypes defined by physiological variables and biomarkers in adults with asthma. Allergy 2014; 69: 1198-1204.
24. Wheelock CE, Goss VM, Balgoma D, et al. Application of 'omics technologies to biomarker discovery in inflammatory lung diseases. Eur Respir J 2013; 42: 802-825.
25. Shaw DE, Sousa AR, Fowler SJ, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J 2015; 46: 1308-1321.
26. Fleming L, Murray C, Bansal AT, et al. The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts. Eur Respir J 2015; 46: 1322-1333.
27. Bel EH, Sousa A, Fleming L, et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 2011; 66: 910-917.
28. Thomson NC, Chaudhuri R, Heaney LG, et al. Clinical outcomes and inflammatory biomarkers in current smokers and exsmokers with severe asthma. J Allergy Clin Immunol 2013; 131: 1008-1016.
29. Thomson NC, Chaudhuri R. Asthma in smokers: challenges and opportunities. Curr Opin Pulm Med 2009; 15: 39-45.
30. Polosa R, Thomson NC. Smoking and asthma: dangerous liaisons. Eur Respir J 2013; 41: 716-726.
31. Heaney LG, Brightling CE, Menzies-Gow A, et al. Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry. Thorax 2010; 65: 787-794.
32. Schleich F, Brusselle G, Louis R, et al. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir Med 2014; 108: 1723-1732.
33. Schleich FN, Chevremont A, Paulus V, et al. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur Respir J 2014; 44: 97-108.
34. Clatworthy J, Price D, Ryan D, et al. The value of self-report assessment of adherence, rhinitis and smoking in relation to asthma control. Prim Care Respir J 2009; 18: 300-305.
35. Broekema M, ten Hacken NH, Volbeda F, et al. Airway epithelial changes in smokers but not in ex-smokers with asthma. Am J Respir Crit Care Med 2009; 180: 1170-1178.
36. de Groot EP, Duiverman EJ, Brand PL. Comorbidities of asthma during childhood: possibly important, yet poorly studied. Eur Respir J 2010; 36: 671-678.
37. de Groot EP, Nijkamp A, Duiverman EJ, et al. Allergic rhinitis is associated with poor asthma control in children with asthma. Thorax 2012; 67: 582-587.
38. Deliu M, Belgrave D, Simpson A, et al. Impact of rhinitis on asthma severity in school-age children. Allergy 2014; 69: 1515-1521.